Demographic and clinical features of the patients with CLL.
| Demographic and baseline clinical features | N=11 (%) |
|---|---|
| Gender, female/male (%) | 4/7 (36.4/63.4) |
| Age, median (range) | 65 (51–80) |
| ECOG performance score≥3 | 1 (9.1) |
| Bulky lesion, N (%) | 2 (18.2) |
| Rai stage≥3, N (%) | 7 (63.6) |
| Del17p, N (%) | 4 (36.4) |
| N of previous treatments | |
| 0–1 | 5 (45.5) |
| 2–3 | 4 (36.4) |
| >3 | 2 (18.1) |
| Previous treatment regimens | |
| R-FC | 7 (63.6) |
| R-CVP | 4 (36.4) |
| R-bendamustin | 3 (27.3) |
| Chlorambucil | 2 (18.2) |
| Other | 4 (36.4) |
| Treatment duration with ibrutinib (mo, median) | 4 (2–18) |
| Side effects of grade≥3 during treatment with ibrutinib | 4 (36.4) |
| Treatment-emergent lymphocytosis, N (%) | 0 (0.0) |
| Hb≤11 (g/dL), N (%) | 6 (54.5) |
| Platelet≤100×109/L, N (%) | 7 (63.6) |
| WBC (103/mL), mean (range) | 47,236 (1,300–182,900) |
| Absolute lymphocyte count (103/mL), mean (range) | 38,200 (300–166,200) |
Blood Res 2020;55:206~212 https://doi.org/10.5045/br.2020.2020158
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd